Sign in

    Blair Cohen

    Research Analyst who previously served at H.C. Wainwright

    Blair Cohen is a Research Analyst who previously served at H.C. Wainwright & Co., specializing in coverage of biotechnology and life sciences companies, notably Kezar Life Sciences. During his tenure at H.C. Wainwright from 2017 to 2020, Cohen participated in earnings calls and research activities, contributing analytical insights to both institutional and retail investors. Blair's professional credentials include FINRA registration as an Investment Adviser. He holds an undergraduate degree from Indiana University, and prior experience includes client solutions and brand strategy roles in the LegalTech sector before fully focusing on equity research.

    Blair Cohen's questions to Kezar Life Sciences (KZR) leadership

    Blair Cohen's questions to Kezar Life Sciences (KZR) leadership • Q2 2020

    Question

    Blair Cohen of H.C. Wainwright inquired about the timeline for the next update from the Stage 1b MISSION study, the impact of COVID-19 on the PRESIDIO trial, the company's cash runway after its recent offering, and the planned initiation and design for the KZR-261 study.

    Answer

    Chief Medical Officer Noreen Henig projected an interim MISSION study update by the end of 2020, with a follow-up in H1 2021. She also noted the PRESIDIO trial timeline is now extended to mid-2022 due to COVID-19, but data integrity should be unaffected. CFO Marc Belsky confirmed the cash runway extends through 2023. President & CSO Christopher Kirk stated the IND for KZR-261 is targeted for Q1 2021, with a trial in solid tumors to begin shortly after.

    Ask Fintool Equity Research AI

    Blair Cohen's questions to Kezar Life Sciences (KZR) leadership • Q2 2020

    Question

    Blair Cohen of H.C. Wainwright inquired about the timeline for the next MISSION Phase Ib study update, the impact of COVID-19 on the PRESIDIO trial, the company's cash runway, and the development plan for KZR-261.

    Answer

    Chief Medical Officer Noreen Henig projected an interim MISSION update by year-end 2020 and noted the PRESIDIO trial completion is now expected in mid-2022 due to COVID-19, with no impact on data integrity. Chief Financial Officer Marc Belsky confirmed the company's cash runway extends through 2023. Chief Scientific Officer Christopher Kirk stated the KZR-261 IND filing is planned for Q1 2021.

    Ask Fintool Equity Research AI